-
1
-
-
64749102956
-
Diabetes: a cardiac condition manifesting as hyperglycemia
-
PID: 18996825
-
Bell DS (2008) Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract 14:924–932. doi:10.4158/EP.14.7.924
-
(2008)
Endocr Pract
, vol.14
, pp. 924-932
-
-
Bell, D.S.1
-
2
-
-
80051952268
-
Implications of new hypertension guidelines in the United States
-
COI: 1:CAS:528:DC%2BC3MXhtVaksrfJ, PID: 21768528
-
Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB (2011) Implications of new hypertension guidelines in the United States. Hypertension 58:361–366. doi:10.1161/HYPERTENSIONAHA.111.175463
-
(2011)
Hypertension
, vol.58
, pp. 361-366
-
-
Bertoia, M.L.1
Waring, M.E.2
Gupta, P.S.3
Roberts, M.B.4
Eaton, C.B.5
-
3
-
-
84901831627
-
Cardiovascular remodelling in coronary artery disease and heart failure
-
PID: 24831770
-
Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. doi:10.1016/S0140-6736(14)60107-0
-
(2014)
Lancet
, vol.383
, pp. 1933-1943
-
-
Heusch, G.1
Libby, P.2
Gersh, B.3
Yellon, D.4
Bohm, M.5
Lopaschuk, G.6
Opie, L.7
-
4
-
-
84875987216
-
Heart Failure. JACC
-
Braunwald E (2013) Heart Failure. JACC. Heart Fail 1:1–20. doi:10.1016/j.jchf.2012.10.002
-
(2013)
Heart Fail
, vol.1
, pp. 1-20
-
-
Braunwald, E.1
-
5
-
-
84890910451
-
National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998–2010
-
PID: 24190958
-
Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM (2013) National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998–2010. Circulation 128:2577–2584. doi:10.1161/CIRCULATIONAHA.113.003668
-
(2013)
Circulation
, vol.128
, pp. 2577-2584
-
-
Chen, J.1
Hsieh, A.F.2
Dharmarajan, K.3
Masoudi, F.A.4
Krumholz, H.M.5
-
6
-
-
70350341465
-
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
-
COI: 1:CAS:528:DC%2BD1MXhsVKmu7%2FE, PID: 19681866
-
Grieve DJ, Cassidy RS, Green BD (2009) Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157:1340–1351. doi:10.1111/j.1476-5381.2009.00376.x
-
(2009)
Br J Pharmacol
, vol.157
, pp. 1340-1351
-
-
Grieve, D.J.1
Cassidy, R.S.2
Green, B.D.3
-
7
-
-
84920778263
-
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes
-
COI: 1:CAS:528:DC%2BC2MXks1Gisw%3D%3D, PID: 25231355
-
Tate M, Chong A, Robinson E, Green BD, Grieve DJ (2015) Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 172:721–736. doi:10.1111/bph.12943
-
(2015)
Br J Pharmacol
, vol.172
, pp. 721-736
-
-
Tate, M.1
Chong, A.2
Robinson, E.3
Green, B.D.4
Grieve, D.J.5
-
8
-
-
43249089631
-
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
-
COI: 1:CAS:528:DC%2BD1cXltFyltrY%3D, PID: 18427132
-
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340–2350. doi:10.1161/CIRCULATIONAHA.107.739938
-
(2008)
Circulation
, vol.117
, pp. 2340-2350
-
-
Ban, K.1
Noyan-Ashraf, M.H.2
Hoefer, J.3
Bolz, S.S.4
Drucker, D.J.5
Husain, M.6
-
9
-
-
52049093652
-
Grieve DJ (2008) GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP
-
COI: 1:CAS:528:DC%2BD1cXhtFCks7bI, PID: 18708025
-
Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS (2008) Grieve DJ (2008) GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478:136–142. doi:10.1016/j.abb.2008.08.001
-
(2008)
Arch Biochem Biophys
, vol.478
, pp. 136-142
-
-
Green, B.D.1
Hand, K.V.2
Dougan, J.E.3
McDonnell, B.M.4
Cassidy, R.S.5
-
10
-
-
0038577144
-
Cardiac function in mice lacking the glucagon-like peptide-1 receptor
-
COI: 1:CAS:528:DC%2BD3sXktFehtLg%3D, PID: 12746281
-
Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M (2003) Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144:2242–2252. doi:10.1210/en.2003-0007
-
(2003)
Endocrinology
, vol.144
, pp. 2242-2252
-
-
Gros, R.1
You, X.2
Baggio, L.L.3
Kabir, M.G.4
Sadi, A.M.5
Mungrue, I.N.6
Parker, T.G.7
Huang, Q.8
Drucker, D.J.9
Husain, M.10
-
11
-
-
0035980166
-
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes
-
COI: 1:STN:280:DC%2BD3MvpvFKktA%3D%3D, PID: 11532906
-
Vila Petroff MG, Egan JM, Wang X, Sollott SJ (2001) Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89:445–452. doi:10.1161/hh1701.095716
-
(2001)
Circ Res
, vol.89
, pp. 445-452
-
-
Vila Petroff, M.G.1
Egan, J.M.2
Wang, X.3
Sollott, S.J.4
-
12
-
-
0036307872
-
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons
-
COI: 1:CAS:528:DC%2BD38XltF2rtbg%3D, PID: 12093887
-
Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43–52. doi:10.1172/JCI15595
-
(2002)
J Clin Invest
, vol.110
, pp. 43-52
-
-
Yamamoto, H.1
Lee, C.E.2
Marcus, J.N.3
Williams, T.D.4
Overton, J.M.5
Lopez, M.E.6
Hollenberg, A.N.7
Baggio, L.8
Saper, C.B.9
Drucker, D.J.10
Elmquist, J.K.11
-
13
-
-
84903807727
-
Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism
-
PID: 25005062
-
Goodwill A, Tune J, Noblet J, Conteh A, Sassoon D, Casalini E, Mather K (2014) Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res Cardiol 109:426. doi:10.1007/s00395-014-0426-9
-
(2014)
Basic Res Cardiol
, vol.109
, pp. 426
-
-
Goodwill, A.1
Tune, J.2
Noblet, J.3
Conteh, A.4
Sassoon, D.5
Casalini, E.6
Mather, K.7
-
14
-
-
4344605042
-
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
-
COI: 1:CAS:528:DC%2BD2cXms1OgtLw%3D, PID: 15313949
-
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955–961. doi:10.1161/01.CIR.0000139339.85840.DD
-
(2004)
Circulation
, vol.110
, pp. 955-961
-
-
Nikolaidis, L.A.1
Elahi, D.2
Hentosz, T.3
Doverspike, A.4
Huerbin, R.5
Zourelias, L.6
Stolarski, C.7
Shen, Y.T.8
Shannon, R.P.9
-
15
-
-
64649102619
-
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
-
COI: 1:CAS:528:DC%2BD1MXktleiu7o%3D, PID: 19151200
-
Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975–983. doi:10.2337/db08-1193
-
(2009)
Diabetes
, vol.58
, pp. 975-983
-
-
Noyan-Ashraf, M.H.1
Momen, M.A.2
Ban, K.3
Sadi, A.M.4
Zhou, Y.Q.5
Riazi, A.M.6
Baggio, L.L.7
Henkelman, R.M.8
Husain, M.9
Drucker, D.J.10
-
16
-
-
58949102483
-
Chronic glucagon-like peptide-1 (GLP-1) infusion sustains LV systolic function and prolongs survival in the spontaneously hypertensive-heart failure prone rat
-
COI: 1:CAS:528:DC%2BD1cXhtV2jsrzF, PID: 19727407
-
Poornima I, Brown S, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP (2008) Chronic glucagon-like peptide-1 (GLP-1) infusion sustains LV systolic function and prolongs survival in the spontaneously hypertensive-heart failure prone rat. Circ Heart Fail 1:153–160. doi:10.1161/CIRCHEARTFAILURE.108.766402
-
(2008)
Circ Heart Fail
, vol.1
, pp. 153-160
-
-
Poornima, I.1
Brown, S.2
Bhashyam, S.3
Parikh, P.4
Bolukoglu, H.5
Shannon, R.P.6
-
17
-
-
77951168113
-
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice
-
COI: 1:CAS:528:DC%2BC3cXltFSmtLk%3D, PID: 20097729
-
Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes 59:1063–1073. doi:10.2337/db09-0955
-
(2010)
Diabetes
, vol.59
, pp. 1063-1073
-
-
Sauve, M.1
Ban, K.2
Momen, M.A.3
Zhou, Y.Q.4
Henkelman, R.M.5
Husain, M.6
Drucker, D.J.7
-
18
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
COI: 1:CAS:528:DC%2BD28XhtlaqsrzK, PID: 17174230
-
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694–699. doi:10.1016/j.cardfail.2006.08.211
-
(2006)
J Card Fail
, vol.12
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
19
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
COI: 1:CAS:528:DC%2BD2MXhtVWju7k%3D, PID: 15616022
-
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146–151. doi:10.2337/diabetes.54.1.146
-
(2005)
Diabetes
, vol.54
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Brand, C.L.4
Yellon, D.M.5
-
20
-
-
58949084130
-
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
-
COI: 1:CAS:528:DC%2BD1MXhsFOgtL4%3D, PID: 19195607
-
Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501–510. doi:10.1016/j.jacc.2008.10.033
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 501-510
-
-
Timmers, L.1
Henriques, J.P.2
de Kleijn, D.P.3
Devries, J.H.4
Kemperman, H.5
Steendijk, P.6
Verlaan, C.W.7
Kerver, M.8
Piek, J.J.9
Doevendans, P.A.10
Pasterkamp, G.11
Hoefer, I.E.12
-
21
-
-
78149493266
-
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
-
PID: 21080957
-
Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes D (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76. doi:10.1186/1475-2840-9-76
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 76
-
-
Liu, Q.1
Anderson, C.2
Broyde, A.3
Polizzi, C.4
Fernandez, R.5
Baron, A.6
Parkes, D.7
-
22
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
COI: 1:CAS:528:DC%2BD2cXhsFeisbY%3D, PID: 14981009
-
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962–965. doi:10.1161/01.CIR.0000120505.91348.58
-
(2004)
Circulation
, vol.109
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
Miske, G.4
Shah, A.5
Elahi, D.6
Shannon, R.P.7
-
23
-
-
84908042187
-
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
-
COI: 1:CAS:528:DC%2BC2cXitVWksrjI, PID: 25117407
-
DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, Qin G, Zhuang S, Zhao TC (2014) Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab 307:E630–E643. doi:10.1152/ajpendo.00109.2014
-
(2014)
Am J Physiol Endocrinol Metab
, vol.307
, pp. 630-643
-
-
DeNicola, M.1
Du, J.2
Wang, Z.3
Yano, N.4
Zhang, L.5
Wang, Y.6
Qin, G.7
Zhuang, S.8
Zhao, T.C.9
-
24
-
-
84904283347
-
Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection
-
COI: 1:CAS:528:DC%2BC2cXosl2jtbo%3D, PID: 25061556
-
Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ (2014) Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 3:507–517. doi:10.1016/j.molmet.2014.04.009
-
(2014)
Mol Metab
, vol.3
, pp. 507-517
-
-
Ussher, J.R.1
Baggio, L.L.2
Campbell, J.E.3
Mulvihill, E.E.4
Kim, M.5
Kabir, M.G.6
Cao, X.7
Baranek, B.M.8
Stoffers, D.A.9
Seeley, R.J.10
Drucker, D.J.11
-
25
-
-
0041375468
-
Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic β cells
-
COI: 1:CAS:528:DC%2BD3sXms1amtrg%3D, PID: 12783880
-
Arnette D, Gibson TB, Lawrence MC, January B, Khoo S, McGlynn K, Vanderbilt CA, Cobb MH (2003) Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic β cells. J Biol Chem 278:32517–32525. doi:10.1074/jbc.M301174200
-
(2003)
J Biol Chem
, vol.278
, pp. 32517-32525
-
-
Arnette, D.1
Gibson, T.B.2
Lawrence, M.C.3
January, B.4
Khoo, S.5
McGlynn, K.6
Vanderbilt, C.A.7
Cobb, M.H.8
-
26
-
-
70349334516
-
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease
-
COI: 1:CAS:528:DC%2BD1MXhtFahtLnF, PID: 19570816
-
Kim S, Moon M, Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol 202:431–439. doi:10.1677/JOE-09-0132
-
(2009)
J Endocrinol
, vol.202
, pp. 431-439
-
-
Kim, S.1
Moon, M.2
Park, S.3
-
27
-
-
0032941026
-
Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in chinese hamster ovary cells
-
COI: 1:CAS:528:DyaK1MXhsFCjt7c%3D, PID: 10067836
-
Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, Bernier M (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in chinese hamster ovary cells. Endocrinology 140:1132–1140. doi:10.1210/endo.140.3.6550
-
(1999)
Endocrinology
, vol.140
, pp. 1132-1140
-
-
Montrose-Rafizadeh, C.1
Avdonin, P.2
Garant, M.J.3
Rodgers, B.D.4
Kole, S.5
Yang, H.6
Levine, M.A.7
Schwindinger, W.8
Bernier, M.9
-
28
-
-
34047205064
-
Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
-
COI: 1:CAS:528:DC%2BD2sXkslSrsb8%3D, PID: 17360951
-
Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS (2007) Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18:1227–1238. doi:10.1681/ASN.2006070778
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1227-1238
-
-
Park, C.W.1
Kim, H.W.2
Ko, S.H.3
Lim, J.H.4
Ryu, G.R.5
Chung, H.W.6
Han, S.W.7
Shin, S.J.8
Bang, B.K.9
Breyer, M.D.10
Chang, Y.S.11
-
29
-
-
77957678974
-
Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients
-
COI: 1:CAS:528:DC%2BC3cXht1WltrrE, PID: 20635178
-
Pugazhenthi U, Velmurugan K, Tran A, Mahaffey G, Pugazhenthi S (2010) Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia 53:2357–2368. doi:10.1007/s00125-010-1849-y
-
(2010)
Diabetologia
, vol.53
, pp. 2357-2368
-
-
Pugazhenthi, U.1
Velmurugan, K.2
Tran, A.3
Mahaffey, G.4
Pugazhenthi, S.5
-
30
-
-
84909955874
-
The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway
-
COI: 1:CAS:528:DC%2BC2cXhsl2nsrrL, PID: 25140997
-
Wu XM, Ou QY, Zhao W, Liu J, Zhang H (2014) The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway. Exp Clin Endocrinol Diabetes 122:608–614. doi:10.1055/s-0034-1384584
-
(2014)
Exp Clin Endocrinol Diabetes
, vol.122
, pp. 608-614
-
-
Wu, X.M.1
Ou, Q.Y.2
Zhao, W.3
Liu, J.4
Zhang, H.5
-
31
-
-
38549128215
-
Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction
-
COI: 1:CAS:528:DC%2BD1cXmt1OhtA%3D%3D, PID: 18180403
-
Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM (2008) Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51:319–325. doi:10.1161/HYPERTENSIONAHA.107.101980
-
(2008)
Hypertension
, vol.51
, pp. 319-325
-
-
Looi, Y.H.1
Grieve, D.J.2
Siva, A.3
Walker, S.J.4
Anilkumar, N.5
Cave, A.C.6
Marber, M.7
Monaghan, M.J.8
Shah, A.M.9
-
32
-
-
33745937115
-
8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice
-
COI: 1:CAS:528:DC%2BD28XnslOltL8%3D, PID: 16648370
-
8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 318:914–921. doi:10.1124/jpet.105.097824
-
(2006)
J Pharmacol Exp Ther
, vol.318
, pp. 914-921
-
-
Green, B.D.1
Lavery, K.S.2
Irwin, N.3
O’Harte, F.P.4
Harriott, P.5
Greer, B.6
Bailey, C.J.7
Flatt, P.R.8
-
33
-
-
65949093707
-
Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyocytes
-
COI: 1:CAS:528:DC%2BD1MXlslOmsLc%3D, PID: 19299911
-
Jeong K, Kwon H, Min C, Pak Y (2009) Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyocytes. Exp Mol Med 41:226–235. doi:10.3858/emm.2009.41.4.025
-
(2009)
Exp Mol Med
, vol.41
, pp. 226-235
-
-
Jeong, K.1
Kwon, H.2
Min, C.3
Pak, Y.4
-
34
-
-
0037311110
-
Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis
-
COI: 1:CAS:528:DC%2BD3sXnvV2gsg%3D%3D, PID: 12527808
-
Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, Suzuki YJ (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63:368–377. doi:10.1124/mol.63.2.368
-
(2003)
Mol Pharmacol
, vol.63
, pp. 368-377
-
-
Kim, Y.1
Ma, A.G.2
Kitta, K.3
Fitch, S.N.4
Ikeda, T.5
Ihara, Y.6
Simon, A.R.7
Evans, T.8
Suzuki, Y.J.9
-
35
-
-
74949131620
-
Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload
-
COI: 1:CAS:528:DC%2BC3cXislWmtA%3D%3D, PID: 20038803
-
Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R (2010) Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 120:254–265. doi:10.1172/JCI40295
-
(2010)
J Clin Invest
, vol.120
, pp. 254-265
-
-
Takeda, N.1
Manabe, I.2
Uchino, Y.3
Eguchi, K.4
Matsumoto, S.5
Nishimura, S.6
Shindo, T.7
Sano, M.8
Otsu, K.9
Snider, P.10
Conway, S.J.11
Nagai, R.12
-
37
-
-
73249126900
-
Inhibition of collagen fibrillogenesis by cells expressing soluble extracellular domains of DDR1 and DDR2
-
COI: 1:CAS:528:DC%2BC3cXjt12kuw%3D%3D, PID: 19900459
-
Flynn LA, Blissett AR, Calomeni EP, Agarwal G (2010) Inhibition of collagen fibrillogenesis by cells expressing soluble extracellular domains of DDR1 and DDR2. J Mol Biol 395:533–543. doi:10.1016/j.jmb.2009.10.073
-
(2010)
J Mol Biol
, vol.395
, pp. 533-543
-
-
Flynn, L.A.1
Blissett, A.R.2
Calomeni, E.P.3
Agarwal, G.4
-
38
-
-
77955270565
-
Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy
-
COI: 1:CAS:528:DC%2BC3cXpvV2gurk%3D, PID: 20488188
-
Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, Taffet GE, Entman ML (2010) Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 49:499–507. doi:10.1016/j.yjmcc.2010.05.005
-
(2010)
J Mol Cell Cardiol
, vol.49
, pp. 499-507
-
-
Haudek, S.B.1
Cheng, J.2
Du, J.3
Wang, Y.4
Hermosillo-Rodriguez, J.5
Trial, J.6
Taffet, G.E.7
Entman, M.L.8
-
39
-
-
84905109590
-
Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart
-
COI: 1:CAS:528:DC%2BC2cXhtlKksL7M, PID: 24899689
-
Lal H, Ahmad F, Zhou J, Yu JE, Vagnozzi RJ, Guo Y, Yu D, Tsai EJ, Woodgett J, Gao E, Force T (2014) Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 130:419–430. doi:10.1161/CIRCULATIONAHA.113.008364
-
(2014)
Circulation
, vol.130
, pp. 419-430
-
-
Lal, H.1
Ahmad, F.2
Zhou, J.3
Yu, J.E.4
Vagnozzi, R.J.5
Guo, Y.6
Yu, D.7
Tsai, E.J.8
Woodgett, J.9
Gao, E.10
Force, T.11
-
40
-
-
40349098058
-
Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis
-
COI: 1:CAS:528:DC%2BD1cXislSjur4%3D, PID: 18204489
-
Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008) Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153(Suppl 1):S137–S153. doi:10.1038/sj.bjp.0707659
-
(2008)
Br J Pharmacol
, vol.153
, pp. 137-153
-
-
Sugden, P.H.1
Fuller, S.J.2
Weiss, S.C.3
Clerk, A.4
-
41
-
-
77951498855
-
Adaptive and maladaptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading
-
COI: 1:CAS:528:DC%2BD1MXhtlyqsLfP, PID: 19919989
-
Divakaran V, Adrogue J, Ishiyama M, Entman ML, Haudek S, Sivasubramanian N, Mann DL (2009) Adaptive and maladaptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail 2:633–642. doi:10.1161/CIRCHEARTFAILURE.108.823070
-
(2009)
Circ Heart Fail
, vol.2
, pp. 633-642
-
-
Divakaran, V.1
Adrogue, J.2
Ishiyama, M.3
Entman, M.L.4
Haudek, S.5
Sivasubramanian, N.6
Mann, D.L.7
-
42
-
-
33646076196
-
GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation
-
COI: 1:CAS:528:DC%2BD28Xht1Cmurs%3D, PID: 16397142
-
Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342–350. doi:10.1161/01.RES.0000202804.84885.d0
-
(2006)
Circ Res
, vol.98
, pp. 342-350
-
-
Xu, J.1
Kimball, T.R.2
Lorenz, J.N.3
Brown, D.A.4
Bauskin, A.R.5
Klevitsky, R.6
Hewett, T.E.7
Breit, S.N.8
Molkentin, J.D.9
-
43
-
-
84905292022
-
Cardiac fibroblasts support cardiac inflammation in heart failure
-
PID: 25086637
-
Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, Maier L, Poller W, Blankenberg S, Schultheiss HP, Tschope C, Westermann D (2014) Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol 109:428. doi:10.1007/s00395-014-0428-7
-
(2014)
Basic Res Cardiol
, vol.109
, pp. 428
-
-
Lindner, D.1
Zietsch, C.2
Tank, J.3
Sossalla, S.4
Fluschnik, N.5
Hinrichs, S.6
Maier, L.7
Poller, W.8
Blankenberg, S.9
Schultheiss, H.P.10
Tschope, C.11
Westermann, D.12
-
44
-
-
76149095197
-
Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts
-
COI: 1:CAS:528:DC%2BC3cXht1ynsr4%3D, PID: 20130739
-
Hantouche CM, Bitar KM, Nemer GM, Obeid MY, Kadi LN, Der-Boghossian AH, Bikhazi AB (2010) Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts. Can J Physiol Pharmacol 88:54–63. doi:10.1139/Y09-095
-
(2010)
Can J Physiol Pharmacol
, vol.88
, pp. 54-63
-
-
Hantouche, C.M.1
Bitar, K.M.2
Nemer, G.M.3
Obeid, M.Y.4
Kadi, L.N.5
Der-Boghossian, A.H.6
Bikhazi, A.B.7
-
45
-
-
84855317103
-
GLP-1 analogue, liraglutide ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet
-
PID: 22038829
-
Mells JE, Fu PP, Sharma S, Olson DE, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA (2011) GLP-1 analogue, liraglutide ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet. Am J Physiol Gastrointest Liver Physiol 302:G225–G235. doi:10.1152/ajpgi.00274.2011
-
(2011)
Am J Physiol Gastrointest Liver Physiol
, vol.302
, pp. 225-235
-
-
Mells, J.E.1
Fu, P.P.2
Sharma, S.3
Olson, D.E.4
Cheng, L.5
Handy, J.A.6
Saxena, N.K.7
Sorescu, D.8
Anania, F.A.9
-
46
-
-
77951812608
-
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
-
COI: 1:CAS:528:DC%2BC3cXmt1Kmurk%3D, PID: 20207816
-
Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y (2010) The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298:H1454–H1465. doi:10.1152/ajpheart.00867.2009
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
, pp. 1454-1465
-
-
Ye, Y.1
Keyes, K.T.2
Zhang, C.3
Perez-Polo, J.R.4
Lin, Y.5
Birnbaum, Y.6
-
47
-
-
32644448320
-
The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy
-
COI: 1:CAS:528:DC%2BD28XhsFCqt74%3D, PID: 16487830
-
Asbun J, Villarreal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47:693–700. doi:10.1016/j.jacc.2005.09.050
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 693-700
-
-
Asbun, J.1
Villarreal, F.J.2
-
48
-
-
38149083367
-
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
-
COI: 1:CAS:528:DC%2BD1cXosFKnsw%3D%3D, PID: 17976835
-
Sonne DP, Engstrom T, Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243–249. doi:10.1016/j.regpep.2007.10.001
-
(2008)
Regul Pept
, vol.146
, pp. 243-249
-
-
Sonne, D.P.1
Engstrom, T.2
Treiman, M.3
-
49
-
-
84911411150
-
Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction
-
PID: 25248433
-
Kain V, Prabhu S, Halade G (2014) Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol 109:444. doi:10.1007/s00395-014-0444-7
-
(2014)
Basic Res Cardiol
, vol.109
, pp. 444
-
-
Kain, V.1
Prabhu, S.2
Halade, G.3
-
50
-
-
59849089688
-
IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR
-
COI: 1:CAS:528:DC%2BD1MXntFahuw%3D%3D, PID: 19096025
-
Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R (2009) IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104:e9–e18. doi:10.1161/CIRCRESAHA.108.188243
-
(2009)
Circ Res
, vol.104
, pp. 9-18
-
-
Krishnamurthy, P.1
Rajasingh, J.2
Lambers, E.3
Qin, G.4
Losordo, D.W.5
Kishore, R.6
-
51
-
-
67249152096
-
Cardiac fibroblasts: at the heart of myocardial remodeling
-
COI: 1:CAS:528:DC%2BD1MXnsFyhtbY%3D, PID: 19460403
-
Porter KE, Turner NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123:255–278. doi:10.1016/j.pharmthera.2009.05.002
-
(2009)
Pharmacol Ther
, vol.123
, pp. 255-278
-
-
Porter, K.E.1
Turner, N.A.2
-
52
-
-
77951151612
-
inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
-
COI: 1:CAS:528:DC%2BC3cXltFSmtL0%3D, PID: 20068138
-
Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H (2010) inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030–1037. doi:10.2337/db09-1694
-
(2010)
Diabetes
, vol.59
, pp. 1030-1037
-
-
Arakawa, M.1
Mita, T.2
Azuma, K.3
Ebato, C.4
Goto, H.5
Nomiyama, T.6
Fujitani, Y.7
Hirose, T.8
Kawamori, R.9
Watada, H.10
-
53
-
-
74249095850
-
Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction
-
COI: 1:STN:280:DC%2BC3c7kvFCjuw%3D%3D, PID: 19228260
-
Troidl C, Mollmann H, Nef H, Masseli F, Voss S, Szardien S, Willmer M, Rolf A, Rixe J, Troidl K, Kostin S, Hamm C, Elsässer A (2009) Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 13:3485–3496. doi:10.1111/j.1582-4934.2009.00707.x
-
(2009)
J Cell Mol Med
, vol.13
, pp. 3485-3496
-
-
Troidl, C.1
Mollmann, H.2
Nef, H.3
Masseli, F.4
Voss, S.5
Szardien, S.6
Willmer, M.7
Rolf, A.8
Rixe, J.9
Troidl, K.10
Kostin, S.11
Hamm, C.12
Elsässer, A.13
-
54
-
-
84961290849
-
Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes
-
COI: 1:CAS:528:DC%2BC2MXisFGqsr4%3D, PID: 25535334
-
Wende AR, O’Neill BT, Bugger H, Riehle C, Tuinei J, Buchanan J, Tsushima K, Wang L, Caro P, Guo A, Sloan C, Kim BJ, Wang X, Pereira RO, McCrory MA, Nye BG, Benavides GA, Darley-Usmar VM, Shioi T, Weimer BC, Abel ED (2015) Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes. Mol Cell Biol 35:831–846. doi:10.1128/MCB.01109-14
-
(2015)
Mol Cell Biol
, vol.35
, pp. 831-846
-
-
Wende, A.R.1
O’Neill, B.T.2
Bugger, H.3
Riehle, C.4
Tuinei, J.5
Buchanan, J.6
Tsushima, K.7
Wang, L.8
Caro, P.9
Guo, A.10
Sloan, C.11
Kim, B.J.12
Wang, X.13
Pereira, R.O.14
McCrory, M.A.15
Nye, B.G.16
Benavides, G.A.17
Darley-Usmar, V.M.18
Shioi, T.19
Weimer, B.C.20
Abel, E.D.21
more..
-
55
-
-
7944219811
-
Extracellular signal regulated kinase and SMAD signalling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27
-
COI: 1:CAS:528:DC%2BD2cXotlKqu7c%3D, PID: 15322702
-
de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM (2004) Extracellular signal regulated kinase and SMAD signalling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 82:678–687. doi:10.1007/s00109-004-0579-3
-
(2004)
J Mol Med
, vol.82
, pp. 678-687
-
-
de Boer, R.A.1
Pokharel, S.2
Flesch, M.3
van Kampen, D.A.4
Suurmeijer, A.J.5
Boomsma, F.6
van Gilst, W.H.7
van Veldhuisen, D.J.8
Pinto, Y.M.9
-
56
-
-
74249083210
-
S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species
-
COI: 1:CAS:528:DC%2BC3cXkt1eguw%3D%3D, PID: 19755413
-
Takuwa N, Ohkura SI, Takashima SI, Ohtani K, Okamoto Y, Tanaka T, Hirano K, Usui S, Wang F, Du W, Yoshioka K, Banno Y, Sasaki M, Ichi I, Okamura M, Sugimoto N, Mizugishi K, Nakanuma Y, Ishii I, Takamura M, Kaneko S, Kojo S, Satouchi K, Mitumori K, Chun J, Takuwa Y (2010) S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 85:484–493. doi:10.1093/cvr/cvp312
-
(2010)
Cardiovasc Res
, vol.85
, pp. 484-493
-
-
Takuwa, N.1
Ohkura, S.I.2
Takashima, S.I.3
Ohtani, K.4
Okamoto, Y.5
Tanaka, T.6
Hirano, K.7
Usui, S.8
Wang, F.9
Du, W.10
Yoshioka, K.11
Banno, Y.12
Sasaki, M.13
Ichi, I.14
Okamura, M.15
Sugimoto, N.16
Mizugishi, K.17
Nakanuma, Y.18
Ishii, I.19
Takamura, M.20
Kaneko, S.21
Kojo, S.22
Satouchi, K.23
Mitumori, K.24
Chun, J.25
Takuwa, Y.26
more..
-
57
-
-
70349616564
-
Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction
-
COI: 1:CAS:528:DC%2BD1MXhtlent73O, PID: 19684189
-
Li L, Okada H, Takemura G, Ki Kosai, Kanamori H, Esaki M, Takahashi T, Goto K, Tsujimoto A, Maruyama R, Kawamura I, Kawaguchi T, Takeyama T, Fujiwara T, Fujiwara H, Minatoguchi S (2009) Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. Am J Physiol Heart Circ Physiol 297:H1504–H1513. doi:10.1152/ajpheart.00194.2009
-
(2009)
Am J Physiol Heart Circ Physiol
, vol.297
, pp. 1504-1513
-
-
Li, L.1
Okada, H.2
Takemura, G.3
Ki, K.4
Kanamori, H.5
Esaki, M.6
Takahashi, T.7
Goto, K.8
Tsujimoto, A.9
Maruyama, R.10
Kawamura, I.11
Kawaguchi, T.12
Takeyama, T.13
Fujiwara, T.14
Fujiwara, H.15
Minatoguchi, S.16
-
58
-
-
0034105968
-
TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice
-
COI: 1:CAS:528:DC%2BD3cXjtFyhtrg%3D, PID: 10802712
-
Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD (2000) TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6:556–563. doi:10.1038/75037
-
(2000)
Nat Med
, vol.6
, pp. 556-563
-
-
Zhang, D.1
Gaussin, V.2
Taffet, G.E.3
Belaguli, N.S.4
Yamada, M.5
Schwartz, R.J.6
Michael, L.H.7
Overbeek, P.A.8
Schneider, M.D.9
-
59
-
-
84911419215
-
Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction
-
COI: 1:CAS:528:DC%2BC2cXhsFymurjJ, PID: 24970469
-
Hofmann U, Knorr S, Vogel B, Weirather J, Frey A, Ertl G, Frantz S (2014) Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail 7:822–830. doi:10.1161/CIRCHEARTFAILURE.113.001020
-
(2014)
Circ Heart Fail
, vol.7
, pp. 822-830
-
-
Hofmann, U.1
Knorr, S.2
Vogel, B.3
Weirather, J.4
Frey, A.5
Ertl, G.6
Frantz, S.7
-
60
-
-
84908110212
-
Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer
-
COI: 1:CAS:528:DC%2BC2cXhsFertLnP, PID: 25200057
-
Ong SG, Lee WH, Huang M, Dey D, Kodo K, Sanchez-Freire V, Gold JD, Wu JC (2014) Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer. Circulation 130:S60–S69. doi:10.1161/CIRCULATIONAHA.113.007917
-
(2014)
Circulation
, vol.130
, pp. 60-69
-
-
Ong, S.G.1
Lee, W.H.2
Huang, M.3
Dey, D.4
Kodo, K.5
Sanchez-Freire, V.6
Gold, J.D.7
Wu, J.C.8
-
61
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3sXhsF2ksbzN, PID: 23992601
-
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326. doi:10.1056/NEJMoa1307684
-
(2013)
N Engl J Med
, vol.369
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
Steg, P.G.4
Davidson, J.5
Hirshberg, B.6
Ohman, P.7
Frederich, R.8
Wiviott, S.D.9
Hoffman, E.B.10
Cavender, M.A.11
Udell, J.A.12
Desai, N.R.13
Mosenzon, O.14
McGuire, D.K.15
Ray, K.K.16
Leiter, L.A.17
Raz, I.18
-
62
-
-
84883745765
-
Alogliptin after Acute coronary syndrome in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3sXhsF2ksbzP, PID: 23992602
-
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after Acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335. doi:10.1056/NEJMoa1305889
-
(2013)
N Engl J Med
, vol.369
, pp. 1327-1335
-
-
White, W.B.1
Cannon, C.P.2
Heller, S.R.3
Nissen, S.E.4
Bergenstal, R.M.5
Bakris, G.L.6
Perez, A.T.7
Fleck, P.R.8
Mehta, C.R.9
Kupfer, S.10
Wilson, C.11
Cushman, W.C.12
Zannad, F.13
|